Un ensayo para evaluar el venetoclax potenciado con cobicistat en combinación con azacitidina en pacientes adultos con leucemia mieloide aguda recién diagnosticada (HO171)
Un ensayo de fase II de un solo grupo para evaluar venetoclax potenciado con cobicistat en combinación con azacitidina (sc) en pacientes adultos con leucemia mieloide aguda (LMA) recién diagnosticada que no se consideran candidatos para regímenes de tratamiento intensivo
The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Gerwin Huls, prof
- Número de teléfono: +3150 361 2354
- Correo electrónico: g.huls@umcg.nl
Ubicaciones de estudio
-
-
-
's-Hertogenbosch, Países Bajos
- Reclutamiento
- NL-Den Bosch-JBZ
-
Contacto:
- A.H.E. Herbers, Dr.
-
Amersfoort, Países Bajos
- Reclutamiento
- NL-Amersfoort-MEANDERMC
-
Contacto:
- M.F. Corsten, Dr.
-
Amsterdam, Países Bajos
- Reclutamiento
- NL-Amsterdam-OLVG
-
Contacto:
- H. Mooij, Dr.
-
Amsterdam, Países Bajos
- Reclutamiento
- NL-Amsterdam-AUMC
-
Contacto:
- C. Alhan, Dr.
-
Arnhem, Países Bajos
- Reclutamiento
- NL-Arnhem-RIJNSTATE
-
Contacto:
- M.L.H. Cuijpers, Dr.
-
Breda, Países Bajos
- Reclutamiento
- NL-Breda-AMPHIA
-
Contacto:
- R.B. Fiets, Dr.
-
Dordrecht, Países Bajos
- Reclutamiento
- NL-Dordrecht-ASZ
-
Contacto:
- P.E. Westerweel, Dr.
-
Eindhoven, Países Bajos
- Reclutamiento
- NL-Eindhoven-MAXIMAMC
-
Contacto:
- L.W. Tick, Dr.
-
Eindhoven, Países Bajos
- Reclutamiento
- NL-Eindhoven-CATHARINA
-
Contacto:
- M.J. Cruijsen, Dr.
-
Enschede, Países Bajos
- Reclutamiento
- NL-Enschede-MST
-
Contacto:
- T.J.F. Snijders, Dr.
-
Groningen, Países Bajos
- Reclutamiento
- NL-Groningen-UMCG
-
Contacto:
- G.A. Huls, Prof. dr.
-
Leeuwarden, Países Bajos
- Reclutamiento
- NL-Leeuwarden-MCL
-
Contacto:
- B. Franken, Dr.
-
Leiden, Países Bajos
- Reclutamiento
- NL-Leiden-LUMC
-
Contacto:
- P.A. von dem Borne, Dr.
-
Maastricht, Países Bajos
- Reclutamiento
- NL-Maastricht-MUMC
-
Contacto:
- C.H.M.J. van Elssen, Dr.
-
Nieuwegein, Países Bajos
- Reclutamiento
- NL-Nieuwegein-ANTONIUS
-
Contacto:
- O. de Weerdt, Dr.
-
Nijmegen, Países Bajos
- Reclutamiento
- NL-Nijmegen-RADBOUDUMC
-
Contacto:
- N.A. de Jonge, Dr.
-
Nijmegen, Países Bajos
- Reclutamiento
- NL-Nijmegen-CWZ
-
Contacto:
- S. de Jonge, Dr.
-
The Hague, Países Bajos
- Reclutamiento
- NL-Den Haag-HAGA
-
Contacto:
- D. van Lammeren, Dr.
-
Zwolle, Países Bajos
- Reclutamiento
- NL-Zwolle-ISALA
-
Contacto:
- T.T. de Waal, Dr.
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
In order to be eligible to participate in this study, a patient must meet all of the following criteria:
-
Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.
-
Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.
-
WHO performance status 0, 1 or 2 (appendix E).
-
Leukocytes < 30 x109/L
-
Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:
- Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
- Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
- Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
-
Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.
-
Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.
-
Written informed consent.
-
Patient is capable of giving informed consent.
-
Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.
Exclusion Criteria:
A patient who meets any of the following criteria cannot be included in this study:
-
Acute promyelocytic leukemia.
-
Myelodysplastic syndrome (MDS).
-
Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).
-
Diagnosis of any previous or concomitant malignancy is an exclusion criterion:
- except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
- except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
-
Blast crisis of chronic myeloid leukemia.
-
Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).
-
Cardiac dysfunction as defined by:
- Myocardial infarction within the last 3 months of study entry, or
- Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
- Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
- Unstable cardiac arrhythmias.
-
History of stroke or intracranial haemorrhage within 6 months prior to registration.
-
Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).
-
History of non-compliance to medical regimens or considered unreliable with respect to compliance.
-
Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
-
Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.
-
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
-
Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.
-
Intolerability, contra-indication or allergy to one of the study drugs.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: single arm arm extension phase
prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1 |
during run-in and extention phase: from Cycle 1 until relapse during run-in and extention phase: from Cycle 1 until relapse during run-in phase: from cycle 2 until relapse during extension phase: from cycle 1 until relapse |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Periodo de tiempo: 6-8 months
|
run-in phase |
6-8 months
|
|
Overall survival (OS).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Periodo de tiempo: 6-8 months
|
run-in phase |
6-8 months
|
|
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Event free survival (EFS).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Relapse-free survival (RFS).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Incidence and severity of adverse events according to CTCAE version 5.0.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Early (30-day and 60-day) mortality (in general, non-leukemic).
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Clonal evolution during treatment.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Cost-savings on venetoclax drug costs.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
|
Adherence to venetoclax and cobicistat.
Periodo de tiempo: 48 months
|
extension phase |
48 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Leucemia Mieloide
- Leucemia
- Enfermedades hemic y linfáticas
- Leucemia Mieloide Aguda
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Tiazoles
- Azoles
- Ácidos nucleicos, nucleótidos y nucleósidos
- Ácidos, acíclico
- Ácidos carboxílicos
- Citidina
- Nucleósidos de pirimidina
- Pirimidinas
- Compuestos AZA
- Nucleósidos
- Ribonucleósidos
- Carbamatos
- Cobicistat
- Azacitidina
- venetoclax
Otros números de identificación del estudio
Otros números de identificación del estudio
- HO171
- 2023 (Subvención/contrato del NIH de EE. UU.)
- 2023-505379-61-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .